Literature DB >> 32126942

Selective Serotonin Reuptake Inhibitors and Intracerebral Hemorrhage Risk and Outcome.

Li Liu1, Matthew Fuller2, Tyler P Behymer3, Yisi Ng4, Thomas Christianson5, Shreyansh Shah6, Nicolas Kon Kam King4,7, Daniel Woo3, Michael L James6.   

Abstract

Background and Purpose- Selective serotonin reuptake inhibitors (SSRIs) have a well-established association with bleeding complications and conflicting reports on outcome after stroke. We sought to evaluate whether pre-intracerebral hemorrhage (ICH) SSRI use increased ICH risk and post-ICH SSRI use improved ICH outcome. Methods- Through post hoc analysis of the ERICH study (Ethnic/Racial Variations of Intracerebral Hemorrhage), SSRI use was categorized into no use, pre-ICH only, pre- and post-ICH use (termed "continuous"), and post-ICH only (termed "new"). Using multivariable modeling, associations were sought between pre-ICH SSRI use and ICH risk in the case-control set, and associations between post-ICH SSRI use and 3-month outcome were analyzed in the ICH case set. Exploratory analyses sought to assess influence of race/ethnicity in models. Results- The final study cohort consisted of 2287 ICH cases and 2895 controls. Pre-ICH SSRI use was not associated with ICH risk (odds ratio, 0.824 [95% CI, 0.632-1.074]) nor potentiation of ICH risk with anticoagulant or antiplatelet use. New post-ICH SSRI use was associated with unfavorable modified Rankin Scale score at 3 months after ICH (odds ratio, 1.673 [95% CI, 1.162-2.408]; P=0.006) in multivariable analyses. Additional propensity score analysis indicated a similar trend but did not reach statistical significance (P=0.107). When stratified by race/ethnicity, multivariable modeling demonstrated reduced ICH risk with pre-ICH SSRI use in Hispanics (odds ratio, 0.513 [95% CI, 0.301-0.875]; P=0.014), but not non-Hispanic whites or blacks, and no associations between post-ICH SSRI use and 3-month outcome in any racial/ethnic group. Conclusions- In a large multiethnic cohort, pre-ICH SSRI use was not associated with increased ICH risk, but post-ICH SSRI use was associated with unfavorable 3-month neurological outcome after ICH. Registration- URL: https://www.clinicaltrials.gov; Unique identifier: NCT01202864.

Entities:  

Keywords:  cerebral hemorrhage; hemorrhage; outcomes assessment; risk; serotonin reuptake inhibitors

Mesh:

Substances:

Year:  2020        PMID: 32126942      PMCID: PMC7147963          DOI: 10.1161/STROKEAHA.119.028406

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  28 in total

Review 1.  Depression and risk of stroke morbidity and mortality: a meta-analysis and systematic review.

Authors:  An Pan; Qi Sun; Olivia I Okereke; Kathryn M Rexrode; Frank B Hu
Journal:  JAMA       Date:  2011-09-21       Impact factor: 56.272

2.  Selective serotonin reuptake inhibitors and risk of hemorrhagic stroke.

Authors:  Jordan Kharofa; Padmini Sekar; Mary Haverbusch; Charles Moomaw; Matthew Flaherty; Brett Kissela; Joseph Broderick; Daniel Woo
Journal:  Stroke       Date:  2007-09-27       Impact factor: 7.914

3.  The association of selective serotonin reuptake inhibitors use and stroke in geriatric population.

Authors:  Chia-Chun Hung; Ching-Heng Lin; Tsuo-Hung Lan; Chin-Hong Chan
Journal:  Am J Geriatr Psychiatry       Date:  2013-02-06       Impact factor: 4.105

Review 4.  Early Selective Serotonin Reuptake Inhibitors for Recovery after Stroke: A Meta-Analysis and Trial Sequential Analysis.

Authors:  Si-Chun Gu; Chang-De Wang
Journal:  J Stroke Cerebrovasc Dis       Date:  2017-12-21       Impact factor: 2.136

5.  Association of cerebrovascular events with antidepressant use: a case-crossover study.

Authors:  Chi-Shin Wu; Sheng-Chang Wang; Yu-Cheng Cheng; Susan Shur-Fen Gau
Journal:  Am J Psychiatry       Date:  2011-03-15       Impact factor: 18.112

6.  Bleeding risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: A meta-analysis of observational studies.

Authors:  Silvy Laporte; Céline Chapelle; Pascal Caillet; Marie-Noëlle Beyens; Florelle Bellet; Xavier Delavenne; Patrick Mismetti; Laurent Bertoletti
Journal:  Pharmacol Res       Date:  2016-08-10       Impact factor: 7.658

7.  Selective serotonin reuptake inhibitors and the risk of stroke: a population-based case-control study.

Authors:  Søren Bak; Ioannis Tsiropoulos; Jens Ole Kjaersgaard; Morten Andersen; Erling Mellerup; Jesper Hallas; Luis Alberto García Rodríguez; Kaare Christensen; David Gaist
Journal:  Stroke       Date:  2002-06       Impact factor: 7.914

8.  Impact of prestroke selective serotonin reuptake inhibitor treatment on stroke severity and mortality.

Authors:  Janne Kaergaard Mortensen; Heidi Larsson; Søren Paaske Johnsen; Grethe Andersen
Journal:  Stroke       Date:  2014-06-03       Impact factor: 7.914

9.  Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial.

Authors: 
Journal:  Lancet       Date:  2018-12-05       Impact factor: 79.321

10.  Prestroke selective serotonin reuptake inhibitor use and functional outcomes after ischaemic stroke.

Authors:  Mark R Etherton; Khawja A Siddiqui; Lee H Schwamm
Journal:  Stroke Vasc Neurol       Date:  2018-01-13
View more
  2 in total

1.  Serotonin-Affecting Antidepressant Use in Relation to Platelet Reactivity.

Authors:  Joseph Grech; Melissa Victoria Chan; Chinedu Ochin; Amber Lachapelle; Florian Thibord; Zoe Schneider; Bongani Brian Nkambule; Paul Charles John Armstrong; Catherine Wallace de Melendez; Katherine L Tucker; Mahdi Garelnabi; Timothy David Warner; Ming-Huei Chen; Andrew Danner Johnson
Journal:  Clin Pharmacol Ther       Date:  2022-01-10       Impact factor: 6.903

2.  Identification of Candidate Blood mRNA Biomarkers in Intracerebral Hemorrhage Using Integrated Microarray and Weighted Gene Co-expression Network Analysis.

Authors:  Feng Jin; Lei Li; Yuehan Hao; Ling Tang; Yuye Wang; Zhiyi He
Journal:  Front Genet       Date:  2021-07-19       Impact factor: 4.599

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.